Results 41 to 50 of about 14,294,829 (187)

A Case of Angioimmunoblastic T-cell Lymphoma (AITL)

Journal of UOEH, 2022
A 84-year-old female noticed erythema over her whole body for several months and was referred to our department for evaluation of her skin eruption. A physical examination revealed millet-sized erythematous papules and macules all over her body, a high body temperature, and a decreased level of consciousness. A laboratory examination showed an elevated
Ayaka, Kaneoka, Yoko, Akamatsu, Reiko, Hara, Akiko, Sugiyama, Mihoko, Setoguchi   +4 more
openaire   +2 more sources

PCR-based clonality detection in angioimmunoblastic T-cell lymphoma

Клиническая онкогематология, 2014
In this article, we discuss the issues of angioimmunoblastic T-cell lymphoma diagnosis, particularly the PCR-based methods of clonality detection. Assessments of T-and B-cell clonality was based on TCRG (Vg-Jg), TCRB (Vb-Jb, Db-Jb), IGH (FR1, FR2, and ...
Yu. V. Sidorova, Ye. Ye. Nikulina, N. G. Chernova, L. G. Gorenkova, Ye. A. Gilyazitdinova, S. K. Kravchenko, A. M. Kovrigina, A. B. Sudarikov   +7 more
doaj   +1 more source

Overlap between EBV‐positive diffuse large B‐cell lymphoma, NOS, in a young patient and angioimmunoblastic T‐cell lymphoma: A diagnostic pitfall

Clinical Case Reports, 2021
There may be significant histopathologic overlap between EBV‐positive DLBCL, NOS, and other diagnoses including angioimmunoblastic T‐cell lymphoma (AITL).
Chae Hwa Kim, Taban Ghaffaripour, Yi Zhou, Jennifer R. Chapman   +3 more
doaj   +1 more source

The curious origins of angioimmunoblastic T-cell lymphoma [PDF]

Current Opinion in Hematology, 2016
Purpose of review Once an obscure disease, recent studies have transformed our understanding of angioimmunoblastic T-cell lymphoma (AITL). In this review, we summarize new major advances in the genetics and biology of AITL.
José R, Cortés, Teresa, Palomero
openaire   +2 more sources

Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma

, 2014
Peripheral T-cell lymphoma (PTCL) encompasses a heterogeneous group of neoplasms with generally poor clinical outcome. Currently 50% of PTCL cases are not classifiable: PTCL-not otherwise specified (NOS).
Connors, J.M., Wilcox, R.A., Staudt, L.M., Rimsza, L.M., Rosenwald, A., Smith, L., the International Peripheral T-cell Lymphoma, Project, Gascoyne, R.D., Iqbal, J., Braziel, R.M., Lim, S.T., Au, W.Y., Wang, C., Geissinger, E., Gaulard, P., Tan, S.Y., Nakamura, S., Vose, J., Seto, M., Weisenburger, D.D., Delabie, J., Lymphoma Leukemia Molecular Profiling, Project, Jaffe, E.S., Cook, J.R., Guo, S., Armitage, J., Martinez, A., Berger, F., Chan, W.C., Greiner, T.C., Tubbs, R.R., Campo, E., Pileri, S.A., Wright, G., Teh, B.T., Ott, G., Piccaluga, P.P., de Leval, L.   +37 more
core   +1 more source

A phase IIa study of the anti‐PD‐L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL‐T trial

British Journal of Haematology, EarlyView.
The AVAIL‐T study, the first evaluation of programmed death ligand 1 (PD‐L1) blockade in relapsed/refractory peripheral T‐cell lymphomas (PTCL), demonstrated limited single agent activity with durable responses seen in a minority. Circulating tumour DNA revealed distinct mutational dynamics and mass cytometry identified perturbed T‐cell subsets ...
Matthew J. Ahearne, Matthew A. Timmins, Charlotte Gaskell, Aimee Jackson, Clare Morland, Sonia Fox, Louise Hopkins, Nadia Nawaz, Susann Lehmann, Marc Wadsley, Caroline Cowley, Jacqueline Shaw, Naeem Khan, Nagesh Kalakonda, Christopher Trethewey, Ram Malladi, Paul Fields, Dima El Sharkawi, Michael Quinn, Nimish Shah, Andrew Davies, Kim Linton, Pam McKay, Rod Johnson, Simon D. Wagner, David Lewis, Graham P. Collins, Christopher P. Fox, Kate Cwynarski   +28 more
wiley   +1 more source

Angioimmunoblastic T-Cell Lymphoma: A Case Report

Cureus, 2022
Previously believed to be an exaggerated immune response and not a lymphoma, angioimmunoblastic T-cell lymphoma (AITL) is now recognized as a rare variant of peripheral T-cell lymphoma with an aggressive clinical course and poor response to current therapies.
Miles, Brittany, Bazuaye-Ekwuyasi, Eseosa A, Mallick, Jayati, Nguyen, Quan D   +3 more
openaire   +2 more sources

Eosinophilia and Hypereosinophilia: A Practical Approach to Navigating a Broad Differential Diagnosis

European Journal of Haematology, EarlyView.
ABSTRACT Eosinophilia, defined as an absolute eosinophil count (AEC) of ≥ 0.5 × 109/L, is a frequently encountered finding with a vast spectrum of potential underlying etiologies. Hypereosinophilia (HE) is defined as AEC > 1.5 × 109/L and may become life‐threatening when eosinophil‐induced organ damage occurs, defining the hypereosinophilic syndrome ...
Stijn Wigerinck, Peter Vandenberghe
wiley   +1 more source

Erythema Multiforme Major in Angioimmunoblastic T-cell Lymphoma

Acta Dermato-Venereologica, 2021
is missing (Short communication)
Shoko Hattori, Fumi Miyagawa, Keiko Fukuda, Kohei Ogawa, Hideo Asada   +4 more
doaj   +1 more source

Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 10, Page 1702-1712, October 2026.
A comprehensive retrospective analysis of 121 immune checkpoint inhibitor‐induced eosinophilic fasciitis cases, including clinical presentation, diagnostic features and treatment outcomes using data from the EADV Task Force ‘Dermatology for Cancer Patients’, two international pharmacovigilance databases and the current literature.
Tristan V. M. Bruijn, Alexandre O. Gérard, Maëlys Labat, Zoe Apalla, Wouter van Binsbergen, Dimitra Koumaki, Valerian Rivet, Frederic Dezoteux, Damien Giacchero, Michael R. Ardern‐Jones, Kara Heelan, Jesse P. Hirner, Ander Mayor, Mariette Labots, Markus V. Starink, Conny J. van der Laken, Vincent Sibaud, Yannick S. Elshot   +17 more
wiley   +1 more source